STIP1 and gastric cancer: Finally, an in vitro study by Horibe et al. [34] has reported that an anti-TPR peptide that blocks the interaction of Hsp90 with the TPR2A domain of STIP1 is capable of inducing cell death in pancreatic, renal, lung, prostate, and gastric cancer cell lines.